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Background: MAPK7/ERK5 (extracellular-signal-regulated kinase 5) functions within a canonical three-tiered MAPK
(mitogen activated protein kinase) signaling cascade comprising MEK (MAPK/ERK kinase) 5, MEKK(MEK kinase)
2/3 and ERK5 itself. Despite being the least well studied of the MAPK-modules, evidence supports a role for
MAPK7-signaling in the pathology of several cancer types.
Methods and results: Fluorescence in situ hybridization (FISH) analysis identified MAPK7 gene amplification in 4 %
(3/74) of non-small cell lung cancers (NSCLC) (enriched to 6 % (3/49) in squamous cell carcinoma) and 2 % (2/95)
of squamous esophageal cancers (sqEC). Immunohistochemical (IHC) analysis revealed a good correlation between
MAPK7 gene amplification and protein expression. MAPK7 was validated as a proliferative oncogenic driver by
performing in vitro siRNA knockdown of MAPK7 in tumor cell lines. Finally, a novel MEK5/MAPK7 co-transfected
HEK293 cell line was developed and used for routine cell-based pharmacodynamic screening. Phosphorylation
antibody microarray analysis also identified novel downstream pharmacodynamic (PD) biomarkers of MAPK7 kinase
inhibition in tumor cells (pMEF2A and pMEF2D).
Conclusions: Together, these data highlight a broader role for dysregulated MAPK7 in driving tumorigenesis within
niche populations of highly prevalent tumor types, and describe current efforts in establishing a robust drug
discovery screening cascade.
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Mitogen activated protein (MAP) kinase signaling pathways
are highly evolutionarily conserved throughout eukaryotes
and represent a key mechanism in the transduction of
intracellular signals. Of the four MAP kinases which exist
in mammalian cells (ERK1/2, JNK, p38 and ERK5 [1–3],
ERK (extracellular-signal-regulated kinase) 5 is the least
well studied and most structurally divergent of the family.
The ERK5 protein, encoded by the MAPK7 gene [4], con-
tains an N-terminal kinase domain and a large C-terminal
segment, containing a transactivation domain and nuclear* Correspondence: Paul.gavine@astrazeneca.com
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unless otherwise stated.localization and export sequences (NLS/NES). ERK5 is the
effector kinase of a canonical kinase module containing;
MEK (MAPK/ERK kinase) 5, MEKK (MEK kinase) 2/3 and
ERK5 itself [5].
Under normal physiological conditions, MEK5 and
ERK5 are activated by growth factors and cellular stresses
[6, 7] and, through the use of embryonic gene knockouts
of MEK5 or MAPK7, have been shown to contribute
largely to blood vessel and cardiac formation during devel-
opment [8, 9]. In vitro muscle differentiation systems have
highlighted prominent roles for ERK5 signaling in muscle
development [10], whilst in adult tissues, the pathway
plays a role in regulating the proliferation and survival of
endothelial cells and various immune-derived cell popula-
tions [11–14].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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role for dysregulated MEK5/ERK5 signaling as a driver
of tumorigenesis in several cancers. Specifically in breast
cancer, increased ERK5 protein levels are associated with
decreased disease-free survival and furthermore, MEK5
expression is up-regulated by constitutive activation of
STAT (signal transducer and activator of transcription) 3,
commonly detected in advanced breast cancer [15, 16].
The ERK5 pathway also appears to play a role in mediat-
ing chemoresistance in breast cancer cells and contributes
to neuregulin signaling in breast cancer cells overexpress-
ing ErbB2 [17, 18]. In prostate cancer, MEK5 is overex-
pressed and is associated with bone metastases, invasive
potential and corresponding poor survival [19]. Further-
more, in hepatocellular carcinoma (HCC), genetic dysreg-
ulation of MAPK7 expression through amplification of
17p11 is detectable in around 50 % of primary HCC tu-
mors [20]. In the same study, preclinical validation work
using small-interfering RNA (siRNA) suppression of
MAPK7 expression in amplified cell lines confirmed a role
for dysregulated MAPK7 in controlling mitotic entry.
In the work reported here, we identified genetic dysreg-
ulation of MAPK7 and protein overexpression in clinical
samples of non-small cell lung cancer (NSCLC) and
esophageal cancer (EC) of Asian origin, using array com-
parative genomic hybridization (aCGH) and FISH (fluor-
escent in-situ hybridization) technologies. Importantly, by
suppressing expression within MAPK7 amplified cell lines,
we were able to validate MAPK7 as a driver of tumor cell
proliferation and engineer a stable cell line assay for
screening of candidate MAPK7 small molecule kinase
inhibitors. Lastly, using reverse-phase protein chip arrays,
our work identified potential pharmacodynamic bio-
markers of MAPK7 kinase inhibition within MAPK7-
amplified tumor cell lines. In summary, the work here
identifies and validates a novel role for dysregulated
MAPK7 as a tumor driver in clinical samples of NSCLC
and EC, and outlines aspects of preliminary work inFig. 1 Representative FISH data showing MAPK7 gene amplification in NSC
(red) and internal CEP17 control (green) genes. MAPK7 non-amplified tumo
and esophageal tumor tissues are shown in images LC035 and EC012, resp
ratio of >2 across at least tumor 50 cellsdeveloping a drug discovery programme to identify novel
small molecule inhibitors of MAPK7 kinase activity.
Results
Identification of dysregulated MAPK7 expression in
Chinese squamous cell lung and esophageal carcinoma
patient samples
To explore MAPK7 tumor expression profiles in Asian
cancer patients, we collected 74 non-small cell lung can-
cers and 95 squamous esophageal cancers of Chinese
origin. Fluorescent in situ hybridization (FISH) analysis
identified high level MAPK7 gene amplification in 4 %
(3/74) of NSCLC (enriched to 6 % (3/49) in squamous cell
carcinoma) and 2 % (2/95) of sqEC (Fig. 1 and Table 1).
In order to investigate correlations between genetic dys-
regulation of MAPK7 expression and corresponding pro-
tein expression, immunohistochemical (IHC) analysis of
the same NSCLC tissue samples was performed. Analysis
revealed that all 3 MAPK7 amplified cases had corre-
sponding high level MAPK7 protein expression (defined
as IHC3+), suggesting a good correlation of MAPK7 gene
amplification with high level protein expression (Fig. 2A
and Additional file 1: Figure S1). Importantly however, this
analysis also identified a high prevalence of MAPK7 pro-
tein expression in the absence of gene amplification, with
20 % of samples (15/74) staining strongly (IHC3+) for
MAPK7 protein expression (Fig. 2B). Of the remaining
samples, 41 % (30/74), 28 % (21/74) and 11 % (8/74)
stained IHC2+, IHC1+ and IHC0 for MAPK7 protein,
respectively.
MAPK7 is a driver of tumor cell proliferation in
dysregulated cell lines
In order to test the hypothesis that dysregulation of
MAPK7 signaling could drive tumor cell proliferation,
we undertook a number of studies to explore the func-
tional consequences of silencing MAPK7 gene expres-
sion in MAPK7 dysregulated tumor cell lines. TwoLC and sqEC tumor tissues. FISH probes were generated for MAPK7
r tissue is represented by image LC016, while MAPK7 amplified lung
ectively. Gene amplification criteria were defined as a MAPK7/CEP17
Table 1 MAPK7 gene amplification prevalence in Chinese
NSCLC and sqEC
Tumor types MAPK7 AMP prevalence
NSCLC 4 % (3/74) (enriched to 3/49 in squamous cell lung)
sqEC 2 % (2/95)
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(KYSE30 and SNU449) and a MAPK7 ‘normal’ cell line
(NCI-H1793), were selected for study. Detailed MAPK7
gene copy number and MAPK7/CEP17 ratios for these
cell lines are tabulated in Additional File 2: Table S1.
FISH staining of cell pellets confirmed MAPK7 gene
amplification in cell lines KYSE30 and SNU449, but not
in NCI-H1793 (Fig. 3a), and Western blotting of lysates
confirmed higher level MAPK7 protein expression in
KYSE30 and SNU449, but lower levels in NCI-H1793
(Fig. 3b – control lanes and Additional file 3: Figure S2).
Next, we performed in vitro transfection of these cell
lines using MAPK7 small interfering RNA (siRNA) to si-
lence MAPK7 gene expression. Cell lines were trans-
fected over a 4-day period and cell lysates were taken for
Western blot analysis of MAPK7 protein expression
(Fig. 3b). In the MAPK7 dysregulated cell lines KYSE30
and SNU449, MAPK7 protein expression was reduced
by 90 and 70 % respectively, using three separate
MAPK7 siRNA constructs. In the NCI-H1793 controlFig. 2 MAPK7 gene amplification correlates with high level protein express
4 cases of NSCLC (3 MAPK7 amplified and 1 non-amplified). b Histogram vi
NSCLC tumor samples. The three MAPK7 amplified samples are shown in recell line, despite low baseline MAPK7 protein expres-
sion, significant expression knockdown of around 60 %
was also achieved. In parallel, and to evaluate the impact
of MAPK7 gene silencing on cell proliferation, identical
transfection groups were assayed using an Acumen-
based ‘live/dead’ cell enumeration assay over a 6 day
period. In the KYSE30 cell line, near complete knock-
down of MAPK7 protein expression using all three of
the MAPK7 siRNA constructs led to significant reduc-
tions in cell proliferation in each case, accompanied by
elevations in the numbers of dead cells to between 20
and 40 % after 6 days. In the SNU449 cell line, partial
MAPK7 knockdown resulted in significant reductions in
the number of live cells after 6 days using 2 of the 3
siRNA constructs, but in this case, with no appreciable
change in dead cell counts. Within the NCI-H1793 con-
trol cell line, knockdown of MAPK7 protein expression
to around 60 % of control levels had no effect on either
cell proliferation or cell death. To further confirm these
findings, we measured the dynamics of cell line growth
over a 6 day period using an Incucyte cell imaging plat-
form. Consistent with the ‘live/dead’ cell assay, MAPK7
knockdown greatly reduced cell proliferation in KYS30
and SNU449 cell lines, but had no effect on NCI-H1793
(Fig. 3d). Two days post-transfection, MAPK7 siRNA-
transfected tumor cells failed to follow the same expo-
nential growth dynamics of the control and scrambled
siRNA treatment groups, instead displaying suppressedion. a Representative FISH and IHC images of MAPK7 expression from
ew of the distribution of MAPK7 IHC scores across the cohort of 74
d within the IHC 3+ category
Fig. 3 MAPK7 amplification correlates with protein expression and drives proliferation in tumor cell lines KYSE30 and SNU449. a Representative
FISH images of the MAPK7 amplified cell lines KYSE30 and SNU449, and the MAPK7 diploid line, H1793. FISH probes were generated for MAPK7
(red) and internal CEP17 control (green) genes. b Western blot MAPK7 protein expression analysis of cell lines following 4 day treatment with
siRNA controls (left 3 lanes in each panel) or MAPK7-directed siRNAs (right 3 lanes in each panel). GAPDH is included as a protein loading control.
c 4 days post-siRNA transfection, tumor cell lines were assessed for cell survival using an Acumen platform and utilizing ‘live/dead’ cell stains (for
details see ‘Methods’). d Following siRNA transfection, cell growth dynamics were captured over a 6 day period in all treatment groups using an
Incucyte cell confluence imaging platform. Treatment groups are represented by colored lines as follows: Light blue – No SiRNA, Dark blue – NC
Dharmacon, Red – NC Qiagen, Purple – MAPK7si2, Gold – MAPK7si4, Turquoise – MAPK7si5
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the degree of cell confluence consistent with the in-
creased cell death observed in the ‘live/dead’cell assay.
Development of a MEK5A/MAPK7 cell-based in vitro
pharmacodynamic ELISA co-expression assay for small
molecule drug screening
To facilitate drug discovery efforts to target the MAPK7-
signaling axis, we next sought to develop a cell-based
pharmacodynamic assay to enable the effective screening
of compounds possessing MAPK7 kinase inhibitory activ-
ity. Although previous reports have documented theability of exogenously added epidermal growth factor
(EGF) to induce direct cellular activation of MAPK7, this
effect is only reliably detectable using a non-quantitative
gel-shift assay [21]. Using a more artificial in vitro system,
Kato et al. co-expressed a constitutively active form of
MEK5 (MEK5CA) with MAPK7 in CHO-K1 cells and
demonstrated the kinase specificity of MEK5 via direct
phosphorylation and activation of MAPK7 [22]. Taking a
similar approach to ensure robust and specific activation
of MAPK7, we generated a stable co-expression system
utilizing MEK5CA and MAPK7 within a HEK293 cell
background. Western blot analysis demonstrated clear
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MEK5CA, and importantly, this phosphorylation could be
blocked using the commercially available and specific
MAPK7 tool compound, XMD8-92 (Fig. 4a) [21]. This
conclusion was further supported by evidence of a ‘gel
shift’ in the molecular weight of MAPK7 upon co-
expression with MEK5CA, indicative of post-translational
modifications (likely phosphorylation). Moreover, upon
pre-treatment with XMD8-92, this gel-shift did not occur
and MAPK7 remained in a lower molecular weight form.
Having achieved a significant and dynamic phospho-
MAPK7 signal detectable by Western blot, we next
sought to develop a higher throughput ELISA-based
phospho-MAPK7 assay. Cell lysates from co-expression
studies were tested and optimized in a custom ‘sandwich
ELISA’ assay using commercially available antibodies pairsFig. 4 Development and validation of a MEK5A/MAPK7 cell-based in vitro p
HEK293 cell transfectants. HEK293 cells were transfected with plasmid vecto
‘Methods’ section). Cell lysates were prepared and analysed using Western
GAPDH. b Using the same cellular lysates, a quantitative sandwich ELISA as
antibody, incubating with lysate and then using a phospho-MAPK7 (T218/Y
using an envision reader. c Further validation of the pMAPK7 ELISA assay w
molecules; 2 MAPK7 inhibitors and 2 unrelated kinase inhibitors (AZD2281(described in ‘Methods’ section), with the results shown in
Fig. 4b. High level expression of phosphorylated MAPK7
protein was detectable using the optimized assay platform
(lane 4), with an acceptable signal:noise ratio observed
upon analysis of XMD8-92 treated cell lysates (lanes 5 and
6). Further validation of this assay was performed using 2
novel small molecules, Gray#18 and Gray#21 (confirmed
as MAPK7 kinase inhibitors using a biochemical kinase
assay) and 2 unrelated kinase inhibitors, AZD2281 (a
PARP inhibitor) and AZD3965 (an MCT1 inhibitor).
MAPK7 half-maximal cellular inhibitory concentrations
(IC50) were determined for all four agents (Fig. 4c).
Identification of downstream biomarkers of MAPK7 activity
To enable more comprehensive characterisation of
MAPK7-pathway signaling, we sought to identify cellularharmacodynamic ELISA co-expression assay. a Western blot analysis of
rs and/or treated with compound as indicated in the matrix (details in
blot to detect phospho-MAPK7 (T218/Y220), total MAPK7, HA-tag and
say was developed by coating ELISA plates with a total MAPK7 capture
220) detection antibody. Phospho-MAPK7 signals were then quantified
as performed by running dose–response experiments with 4 small
and AZD3965)
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tein array (RPPA) platform. Protein extracts were prepared
from KYSE30 cells, treated (and untreated) for 2 h with
10 μM XMD8-92, and then applied to the antibody micro-
array. Quality control and data normalization was per-
formed using a standardized and validated antibody set
and actual array chip images are shown in Fig. 5a. Follow-
ing automated array chip analysis, of 1,318 antibodies (de-
tails contained in ‘Methods’ section) we identified 5
showing significant signal modulation upon treatment
with XMD8-92. Compared to untreated control cells,
pCDC25C (S216), pCDKN1 (T145), pMEF2A (S408) and
pMEF2D (S444) all showed significant reductions with ‘%
of control’ values of 39.8, 41.9, 44.7 and 45.1, respectively
(Table 2). To corroborate these findings, direct pMEF2A
modulation by MAPK7 inhibition was confirmed by im-
munoblot analysis using an antibody raised against phos-
phorylated Thr312 of MEF2A (Fig. 5b).
Discussion
Dysregulated MAPK7 signaling has been demonstrated to
play key roles in uncontrolled cell proliferation across sev-
eral tumor types [15, 17, 19]. The data herein provide a
first description of the identification of clinical squamous
cell lung and esophageal tumor samples harbouring gene
amplified and overexpressed MAPK7. Intriguingly, in
addition to the 3 clinical cases showing a correlation be-
tween MAPK7 amplification and high level protein expres-
sion (IHC3+), we also identified a further 12 cases with
IHC3+ protein staining in the absence of MAPK7 amplifi-
cation, raising the question of whether MAPK7 gene amp-
lification, protein overexpression, or both, are required for
driving tumor proliferation. Despite our cell lines showing
a good correlation between MAPK7 gene copy number/A
Fig. 5 Phosphorylation antibody microarray analysis of KYSE30 cells treated
cells were treated (or not) for 2 h with 10 μM XMD8-92 and cell lysates we
Actual microarray visualizations are presented. b KYSE30 cells were treated
prepared for Western blotting using antibodies to detect pMEF2A (T312), tratio and protein expression (Additional file 2: Table S1
and Fig. 3b), we were unable to fully answer this question
with the cell lines and samples available. However, this re-
mains a key question and is a focus of ongoing efforts in a
research environment where the development of compan-
ion diagnostics for molecularly targeted therapeutic agents
is increasingly required to ensure accurate selection of
those patients most likely to benefit. Albeit within a rela-
tively small number of lung cancer samples, gene ampli-
fication and overexpression of MAPK7 appeared to be
a distinct molecular feature, as of the 3 samples, only 1
contained an EGFR L858R mutation and none had
KRas mutation (data not shown). Although our data
demonstrate coordinate MAPK7 gene amplification and
protein overexpression, it should be noted that previous
studies have identified additional mechanisms through
which MAPK7 activity can be regulated [23, 24]. De-
tailed exploration of the precise molecular mechanisms
of MAPK7 dysregulation was outwith the scope of our
work here, however our data do suggest that dysregulated
MAPK7 may provide a further level of disease segmenta-
tion within squamous cell lung cancer, which crucially, is
a disease with high unmet need and currently has no ap-
proved targeted therapeutics [25].
Targeted siRNA knockdown of MAPK7 in two dysreg-
ulated cell lines confirmed a driving role for MAPK7 in
tumor cell proliferation in vitro. Interestingly, although a
good correlation was observed between MAPK7 gene
amplification and protein expression in both cell lines,
targeted knockdown had slightly different functional ef-
fects. Partial knockdown of MAPK7 expression in the
SNU449 cell line resulted in anti-proliferative activity
but no appreciable increase in cell death above control
levels. In contrast, near-complete suppression of MAPK7B
with XMD8-92 and confirmation of pMEF2A modulation. a KYSE30
re then prepared and analysed using phospho-antibody microarray.
for 2 h with a range of XMD8-92 concentrations and cell lysates
otal MEF2A and GAPDH
Table 2 Protein targets identified from phosphorylation
antibody microarray
Protein target Signal SEM
(%)(% of control)
CDC25C (p-S216) 39.80 % 2
CDKN1 (p-T145) 41.90 % 3.9
MEF2A (p-S408) 44.70 % 1.9
MEF2D (p-S444) 45.10 % 0.5
MEF2A (p-T312) 54.50 % 7.4
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proliferative activity and significant increases in cell death
above background levels. It is currently unclear whether
this difference was attributable to variation in the degree
of siRNA MAPK7 suppression, or perhaps due to the cel-
lular background and pathway ‘wiring’. Importantly how-
ever, significant suppression of MAPK7 expression and a
lack of any effect on cell proliferation or cell death in the
non-dysregulated MAPK7 cell line, NCI-H1793, con-
firmed a role for dysregulated MAPK7 in driving uncon-
trolled cell proliferation. The relatively benign effect of
MAPK7 suppression in the MAPK7 ‘normal’ NCI-H1793
cell line is consistent with the results of previous inducible
genetic MAPK7 knockout studies in adult mice, which
despite perturbing vascular integrity, had no wider effects
on the whole animal [11].
To facilitate validation of our cell-based MAPK7 phar-
macodynamic ELISA assay and provide a positive con-
trol in our biomarker screen, XMD8-92 served as an
excellent tool compound due to its highly selective na-
ture. Profiling of this agent against a panel of 402 diverse
kinases identified MAPK7 as the most potently inhibited
kinase (dissociation constant, KD = 80nM), followed by
DCAMKL2 (KD = 190nM), TNK1 (KD = 890nM) and
PLK4 (KD = 600nM) [21]. Notably, none of these three
kinases are known to have any associations with MAPK7
biology and indeed, perform roles in cellular processes
highly distinct to that of MAPK7. Interestingly, and in
contrast to the MAPK7 gene knockout work described
above, in vivo studies using XMD8-92 did not lead to
any vascular abnormalities, supporting the concept that
targeting MAPK7 kinase activity (as opposed to whole
gene knockout) may be a viable therapeutic strategy.
Our identification of MEF2A and MEF2D (‘myocyte en-
hancer factors’) as novel pharmacodynamic biomarkers
of MAPK7 inhibition is notable. These transcription fac-
tors bind and activate the transcription of numerous
muscle-specific, growth-factor and stress controlled
genes involved primarily in (but not limited to) skeletal
and cardiac muscle development. Interestingly however,
oncogenic activity has been attributed to MEF2D fu-
sion proteins in acute lymphoblastic leukaemia [26],
underlining a broader role for MAPK7 signaling inoncogenesis. Modulation of CDC25C (pSer216) and
CDKN1 (pThr145) indirectly by XMD8-92 treatment
are consistent with previously suggested roles for dys-
regulated MAPK7 in controlling mitotic entry [20]. Al-
though we were able to confirm modulation of MEF2A
(pThr312) by XMD8-92 using immunoblot analysis,
direct confirmation of the additional biomarkers was
not possible due to a lack of high quality antibodies.
Efforts are currently ongoing to generate antibody re-
agents and perform further evaluation.
Conclusions
Taken together, our data provide the first reported inci-
dences of dysregulated MAPK7 expression in clinical sam-
ples of squamous cell lung and esophageal carcinoma.
Using MAPK7 siRNA, we validate a role for dysregulated
MAPK7 in driving cell proliferation in established tumor
cell lines and describe the development of a cell based
ELISA assay to support screening of novel MAPK7 kinase
inhibitors. Finally, we highlight the identification of several
putative novel pharmacodynamic biomarkers of cellular
MAPK7 signaling. This data affirms MAPK7 as an attract-
ive therapeutic oncology target and outlines aspects of
preliminary work in developing a drug discovery program
to identify novel small molecule inhibitors of MAPK7 kin-
ase activity.Methods
Clinical samples and cell lines
74 NSCLC and 95 sqEC cancer clinical samples were col-
lected from Beijing tumor hospital (Beijing, China) with
signed patient informed consent. This study was approved
by the ethics committee of the Beijing tumor hospital. Cell
lines were obtained from commercial sources (American
Type Culture Collection, Japan Health Science Research
Resource Bank) or from AstraZeneca internal cell banks.
FISH detection
The MAPK7 FISH probe was generated internally by
directly labeling BAC (CTD-2387H16) DNA with
Spectrum Red (Vysis, Cat # 30–803400). The CEP17-
Spectrum Green probe (Vysis, 32–132017) for the
centromeric region of chromosome 17 was used as in-
ternal control.
FISH assays were performed on 4 μm dewaxed and
dehydrated FFPE sections. The SpotLight Tissue pretreat-
ment Kit (Invitrogen, 00–8401) was used for pretreatment
(boiled in reagent 1 for ~15 min then coated with reagent
2 for ~10 min, minor time adjustments were made for in-
dividual samples). Sections and probes were codenatu-
rated at 80 °C for 5 min and then hybridized at 37 °C for
48 h. After a quick post wash off process (0.3 % NP40/1 ×
SSC at 75.5 °C for 5 min, twice in 2 × SSC at room
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with 0.3 μg/ml DAPI (Vector, H-1200), and stored at 4 °C
avoiding light for at least 30 min prior to scoring.
siRNA transfection
In vitro siRNA transfection was performed using HiPer-
Fect transfection reagent (Qiagen) following the manufac-
turer’s protocol. Briefly, cells (1 × 104/well in 96-well plate
or 2 × 105/well in 6-well plate) were transfected with 40
nM of MAPK7 siRNAs (Sigma) or non-silencing siRNAs
(Dharmacon) as control. The confluence of cells reflecting
cell growth was monitored by Incucyte (Essen) over time
after siRNA treatment. At 96 h post transfection, the cells
were staining with final concentration of 1.5 μM of propi-
dium iodide (Invitrogen, P3566) and 10 μM of Hoechst
(Invitrogen, H21486), and the survival rate of cells was de-
tected by Acumen X3 (TTP LabTech).
Western blotting
Ninety-six h post siRNA transfection, cell lysates were
collected and subjected to SDS/PAGE and transferred
on to PVDF membrane. The membrane was blocked
with 5 % skimmed milk in TBS-Tween20 overnight at
4 °C, before being incubated with primary antibody for
2 h at room temperature or overnight at 4 °C. After
washing, the membrane was incubated with HRP (horse-
radish peroxidase)-conjugated secondary antibody for
1 h at room temperature. Signals were visualized using
Amersham ECL detection reagents (GE health). The pri-
mary antibodies included: MAPK7 antibody (CST,
#3552), pMAPK7 (T218/Y220) (CST, #3371), pMEF2A
(T312) (Abcam, ab#30644), MEF2A (Abcam, ab#32866),
and HA (Roche, #11 583 816 001).
Generation of HEK293 cells coexpressing MEK5CA and
MAPK7
The constitutively active MEK5 (MEK5CA) and MAPK7
plasmids were constructed as published [22]. HEK293
cells were seeded at 5,000,000/100 ml/T150 flask over-
night and then co-transfected with 10 μg MEK5CA and
10 μg MAPK7 by using 60 μl of Roche X-treme Gene 9
DNA transfection reagent (Roche, #6365779001) for 48 h.
Cells were then harvested and frozen down in aliquots.
Cell-based pMAPK7 ELISA surrogate PD assay
Co-transfected HEK293 cells (described above) were ali-
quotted and seeded at a density of 10,000 cells/100 μl/
96-well for 4 h, and then treated with various concentra-
tions of XMD8-92 for 2 h at 37 °C in a cell incubator
(Thermo). After washing out cell culture medium,
110 μl/well of RIPA-cocktail buffer was added to lyse the
cells overnight. On the same day, 96-well NUNC plates
(PerkinElmer, AAAND-0001) were coated with 100 μl/
well of MAPK7 capture antibody (R&D, AF2848) at1 μg/ml at 4 °C overnight. Next day, plates were then
washed with buffer (PBS containing 0.05 % Tween20) 3
times, and blocked with 2 % BSA-wash buffer for 1 h.
Cell lysates were then added (100 μl/well) for 2 h,
followed by washing 3 times. pMAPK7 (T218/Y220) de-
tection antibody (Santa Cruz, sc-135761) was added at
5 μg/ml for 2 h, and plates then washed before incubat-
ing with secondary antibody (PerkinElmer, AD0207) for
1 h. Plates were given a final wash, enhancement solu-
tion added (PerkinElmer, 1244-104) for 30 min, before
reading on the Envision reader(PerkinElmer).Phosphorylation antibody microarray
The phosphorylation explorer antibody microarray chip
PEX100, containing 1,318 well-characterized site-
specific antibodies, was purchased from Full Moon Bio-
systems (Sunnyvale, CA, USA). Details of these anti-
bodies can be accessed via the vendors website (http://
www.fullmoonbio.com/product/phospho-explorer-anti-
body-array/). KYSE30 cells (2 × 107 cells per 10-cm
plate) were treated with or without 10 μM XMD8-92
for 2 h. Cells were washed with cold 1X PBS (4 °C) and
collected by scraping from the plate. Cells were spun
briefly in a microcentrifuge to remove culture media
from the cells. Three additional washes were performed
using cold 1X PBS (4 °C). Cells were centrifuged again
at 4 °C and supernatant discarded. Cell pellets were
shipped to the vendor and antibody microarray’s run
according to the manufacturer’s instruction. Duplicate
chips were run for both control and treated lysates
groups and ‘% of control’ values calculated according to
normalised average plate readings.Additional files
Additional file 1: Figure S1. Representative FISH and IHC staining
images of NSCLC tissue samples. Circled numbers within the IHC images
refer to ‘IHC 1+’ and ‘IHC 2+’ staining intensities.
Additional file 2: Table S1. Detailed cell line MAPK7 FISH data.
Additional file 3: Figure S2. Western blot analysis of tumor cell lines
for Erk5 protein. Cell lysates were prepared and analysed for detection of
total Erk5 and GAPDH as described in ‘materials and methods’.Competing interest
The following initialled authors are full time employees of AstraZeneca: PRG,
MW, EH, CH, JX, XS, JF, TZ, LZ, LH and QJ. The authors declare no other
competing interests.
Authors’ contributions
EH, CH, MW and JX carried out the in vitro cell line work. XS, JF, TZ, QY and
LZ performed FISH, IHC and pathology analyses. LX, LH performed in vivo
and microarray studies. PRG, MW and DY conceived the studies, participated
in their design and coordination and helped to draft the manuscript. QJ
reviewed and approved the studies. All authors read and approved the final
manuscript.
Gavine et al. BMC Cancer  (2015) 15:454 Page 9 of 9Acknowledgements
We gratefully acknowledge the support of Xie Liang and Luna Han in
generating in vivo pharmacodynamic assays and animal models.Research support
All of the work described was funded by AstraZeneca.
Author details
1Innovation Center China, AstraZeneca Global R&D, Zhangjiang Hi-Tech Park,
Shanghai 201203, People’s Republic of China. 2Shanghai Chest Hospital,
Shanghai, People’s Republic of China. 3Shanghai Zhongshan Hospital,
Shanghai, People’s Republic of China.
Received: 5 November 2014 Accepted: 20 May 2015
References
1. Raman M, Chen W, Cobb MH. Differential regulation and properties of
MAPKs. Oncogene. 2007;26:3100–12.
2. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature.
2001;410:37–40.
3. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al.
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological
functions. Endocr Rev. 2001;22:153–83.
4. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase
signal transduction pathway. J Biol Chem. 1995;270:12665–9.
5. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian
map kinase. Biochem Biophys Res Commun. 1995;213:715–24.
6. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee JD. Big mitogen-activated
protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem.
1996;271:16586–90.
7. Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/
BMK1 by receptor tyrosine kinases. Identification and characterization of a
signaling pathway to the nucleus. J Biol Chem. 1999;274:26563–71.
8. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG, et al.
Targeted deletion of mek5 causes early embryonic death and defects in the
extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell
survival pathway. Mol Cell Biol. 2005;25:336–45.
9. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. Erk5 null mice display
multiple extraembryonic vascular and embryonic cardiovascular defects.
Proc Natl Acad Sci U S A. 2002;99:9248–53.
10. Dinev D, Jordan BW, Neufeld B, Lee JD, Lindemann D, Rapp UR, et al.
Extracellular signal regulated kinase 5 (ERK5) is required for the
differentiation of muscle cells. EMBO Rep. 2001;2:829–34.
11. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, et al.
Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity
and leads to endothelial failure. J Clin Invest. 2004;113:1138–48.
12. Sohn SJ, Lewis GM, Winoto A. Non-redundant function of the MEK5-ERK5
pathway in thymocyte apoptosis. EMBO J. 2008;27:1896–906.
13. Rovida E, Spinelli E, Sdelci S, Barbetti V, Morandi A, Giuntoli S, et al. ERK5/
BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-in-
duced proliferation in macrophages in a Src-dependent fashion. Journal of
immunology (Baltimore, Md: 1950). 2008;180:4166–72.
14. Garaude J, Cherni S, Kaminski S, Delepine E, Chable-Bessia C, Benkirane M,
et al. ERK5 activates NF-kappaB in leukemic T cells and is essential for their
growth in vivo. Journal of immunology (Baltimore, Md: 1950).
2006;177:7607–17.
15. Song H, Jin X, Lin J. Stat3 upregulates MEK5 expression in human breast
cancer cells. Oncogene. 2004;23:8301–9.
16. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparis-Ogando A.
Expression of Erk5 in early stage breast cancer and association with disease
free survival identifies this kinase as a potential therapeutic target. PLoS
One. 2009;4, e5565.
17. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, et al.
Identification of mitogen-activated protein kinase kinase as a chemoresistant
pathway in MCF-7 cells by using gene expression microarray. Surgery.
2002;132:293–301.
18. Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella
A. Erk5 participates in neuregulin signal transduction and is constitutively active
in breast cancer cells overexpressing ErbB2. Mol Cell Biol. 2002;22:270–85.19. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, et al. MEK5
overexpression is associated with metastatic prostate cancer, and stimulates
proliferation, MMP-9 expression and invasion. Oncogene. 2003;22:1381–9.
20. Zen K, Yasui K, Nakajima T, Zen Y, Zen K, Gen Y, et al. ERK5 is a target for
gene amplification at 17p11 and promotes cell growth in hepatocellular
carcinoma by regulating mitotic entry. Genes Chromosomes Cancer.
2009;48:109–20.
21. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, et al.
Pharmacological inhibition of BMK1 suppresses tumor growth through
promyelocytic leukemia protein. Cancer Cell. 2010;18:258–67.
22. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5
regulates serum-induced early gene expression through transcription factor
MEF2C. EMBO J. 1997;16:7054–66.
23. Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero
ML, Esparís-Ogando A, et al. ERK5/BMK1 is a novel target of the tumor
suppressor VHL: implication in clear cell renal carcinoma. Neoplasia.
2013;15:649–59.
24. Buschbeck M, Ullrich A. The unique C-terminal tail of the mitogen-activated
protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol
Chem. 2005;280:2659–67.
25. Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung
cancer. Oncologist. 2013;18:707–16.
26. Prima V, Hunger SP. Cooperative transformation by MEF2D/DAZAP1 and
DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute
lymphoblastic leukemia. Leukemia. 2007;21:2470–5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
